• Flatiron’s AI-Powered Platform, Verana Health Ovarian Cancer Database, Eir Partners Invests in QuartzBio

    Clinical Research News | uMotif launches its new Scientific Consulting Services; Veeva Systems announces Veeva Falcon; b.well Connected Health and myTomorrows announce a partnership; and more.

    May 29, 2026

  • Insider Views on the FDA’s Evolving Relationship with AI

    Clinical Research News | The Food and Drug Administration is undergoing a major step change in how it regulates and evaluates drugs, marked by a shift toward real-time clinical trials, an agency-wide rollout of generative AI tools to speed up drug application reviews, and a radical transparency push that includes public disclosure of complete response letters sent to pharmaceutical companies explaining why a drug application was rejected.

    May 27, 2026

  • Follow the Money: AI Drug Design Engine Development, Multiple Myeloma Trials, More

    Clinical Research News | Isomorphic Labs continues to develop its AI drug design engine; CellCentric advances in multiple myeloma; and more.

    May 26, 2026

  • Data is Both the Fuel and Downfall of AI in Drug Development

    Clinical Research News | High-impact opportunities for leveraging AI across the pharmaceutical R&D cycle are too numerous to count but won’t “automagically” solve any of the longstanding problems in ushering molecules to market. AI requires human attention to match tools to tasks for ensuring the accuracy of model predictions, and the pitfalls are dangerously easy to miss, according to a Novo Nordisk presentation at this week’s Scope X conference in Boston.

    May 21, 2026

  • Bacteria: Unsung Players in the Tumor Microbiome

    Clinical Research News | How cancer patients will respond to treatment can be anticipated based on their genetics as well as the tumor microenvironment, although one relevant component is often all but dismissed: the tumor microbiota. This is despite an abundance of evidence that a cancer’s microbial community plays a major role not only in therapeutic effects but also in tumor development, progression, and metastasis formation.

    May 20, 2026

  • FDA Conversation on Selective Safety Data Collection

    Clinical Research News | Earlier this month, TransCelerate BioPharma released a summary report focused on selective safety data collection (SSDC) gathered during a joint tabletop exercise convened in late 2025 in collaboration with U.S. Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER) Center for Clinical Trial Innovation (C3TI).

    May 19, 2026